Plasma thrombomodulin levels in lung cancer patients
| dc.contributor.author | Yılmaz, T. | |
| dc.contributor.author | Akman, M. | |
| dc.contributor.author | Tutluoğlu, Bülent | |
| dc.contributor.author | Afrasyap, Lale | |
| dc.contributor.author | Göylüsün, Veli | |
| dc.contributor.author | Çelik, N. | |
| dc.date.accessioned | 2024-07-12T21:10:37Z | |
| dc.date.available | 2024-07-12T21:10:37Z | |
| dc.date.issued | 1999 | en_US |
| dc.department | Fakülteler, Tıp Fakültesi | en_US |
| dc.description.abstract | BACKGROUND: Thrombomodulin (TM) is a glycoprotein and besides its anticoagulant property it is accepted as an onco developmental antigen. Considering these properties we hypothesised that active TMB might have a role in cancer cell behaviour. METHODS: We measured serum TMB levels by the enzyme immunoassay method in 40 patients with lung cancer and 20 healthy subjects. RESULTS: TMB levels were found as 54.6 +/- 11.5 in controls and 60.9 +/- 31.2 ng/ml in lung cancer patients TM levels were 59.4 +/- 24.2 ng/ml in 24 epidermoid carcinoma patients, 65 +/- 50.2 ng/ml in 10 small cell carcinoma patients and 60 +/- 18.4 ng/ml in 6 adenocarcinoma patients. Patients with stage 4 and distant metastasis had a value of 65 +/- 33.9 ng/ml. No significant differences were found between healthy subjects and cancer patients. Also the differences between 3 groups of patients were insignificant. CONCLUSIONS: It was concluded that serum TMB levels could not be accepted as a tumour marker in lung cancer patients. | en_US |
| dc.identifier.citation | Yilmaz, T., Akman, M., Tutluoğlu, B., Afrasyap, L., Göylüsün, V., ve Çelik, N. (1999). Plasma thrombomodulin levels in lung cancer patients. Panminerva medica, Edizioni Minerva Medica. 41(2), s.125-128 . | en_US |
| dc.identifier.endpage | 128 | en_US |
| dc.identifier.issn | 0031-0808 | |
| dc.identifier.issn | 1827-1898 | |
| dc.identifier.issue | 2 | en_US |
| dc.identifier.scopusquality | Q3 | en_US |
| dc.identifier.startpage | 125 | en_US |
| dc.identifier.uri | https://www.minervamedica.it/en/journals/panminerva-medica/article.php?cod=R41Y1999N02A0125 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12415/4268 | |
| dc.identifier.volume | 41 | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Edizioni Minerva Medica | en_US |
| dc.relation.ispartof | Panminerva Medica | en_US |
| dc.relation.publicationcategory | Uluslararası Editör Denetimli Dergide Makale | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.snmz | KY03209 | |
| dc.title | Plasma thrombomodulin levels in lung cancer patients | en_US |
| dc.type | Article | |
| dspace.entity.type | Publication |
